Table 2.
Variation of the two indicators (expressed as a percentage of the observed mean value during the analyzed period) by subgroup and API in La Gomera and in Spain. Data from Spain were extracted from the report on the “Use of opioid drugs in Spain during the 2010–2019 period” published by The Spanish Agency for Medicines and Medical Devices in 2019 (AEMPS 2020)
| La Gomera | Spain | ||
|---|---|---|---|
| Subgroup /API | % units sold | % DID | % DID |
| N02AA01-Morphine | 2.22 | 1.83 | 1.58 |
| N02AA03-Hydromorphone | 0.09 | 0.12 | 0.29 |
| N02AA05-Oxycodone | 0.40 | 0.24 | 0.67 |
| N02AA55-Oxycodone_Naloxone | 1.58 | 2.71 | 3.49 |
| N02AB02-Pethidine | 0.02 | < 0.001 | 0.02 |
| N02AB03-Fentanyl | 6.29 | 14.87 | 16.10 |
| N02AE01-Buprenorphine | 1.33 | 15.75 | 4.62 |
| N02AJ13_Tramadol_Acetaminophen | 63.35 | 34.73 | 49.43 |
| N02AJ14_Tramadol_Dexketoprofen | 6.12 | 3.98 | 1.27 |
| N02AX02-Tramadol | 13.80 | 19.96 | 17.58 |
| N02AX06-Tapentadol | 4.79 | 5.82 | 4.95 |